Biogen’s Spinraza Stays Ahead Of Novartis And Roche Challengers In SMA – For Now

Evrysdi Growing Fast

 
• By Andrew McConaghie
  
Spinraza
Spinraza was the first treatment to offer hope to children with SMA, but Zolgensma and Evrysdi are now providing new options. • Source: Alamy

More from Business

More from Scrip